Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12202700 | 0.80 | DPP4 (0.40) | DPP4 | |
| SCHEMBL14567809 | 0.78 | TUBB1 (0.48) | TUBB1 | |
| SCHEMBL57849 | 0.78 | TUBB1 (0.48) | TUBB1 | |
| SCHEMBL13751416 | 0.78 | TUBB1 (0.48) | TUBB1 | |
| SCHEMBL57601 | 0.74 | TUBB1 (0.61) | DPP4TUBB1 | |
| SCHEMBL16861443 | 0.73 | TUBB1 (0.33) | TUBB1 | |
| SCHEMBL22643755 | 0.73 | TUBB1 (0.33) | TUBB1 | |
| SCHEMBL5578335 | 0.73 | TUBB1 (0.33) | TUBB1 | |
| SCHEMBL16862667 | 0.73 | TUBB1 (0.33) | TUBB1 | |
| SCHEMBL5578339 | 0.73 | TUBB1 (0.33) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | SORRENTO THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | DPP4 3375/4885TUBB1 1159/4885 |
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | ERBB2, ABCG2, DYNLL2 | DPP4 2884/4885TUBB1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.